Mesoblast Liabilities 2025

Mesoblast Aktienanalyse

What does Mesoblast do?

Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Mesoblast's Liabilities

Mesoblast's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Mesoblast's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Mesoblast's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Mesoblast's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Mesoblast’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Mesoblast stock

What is the level of liabilities of Mesoblast this year?

Mesoblast has a debt balance of 187.24 M USD this year.

What were the liabilities of Mesoblast compared to the previous year?

The liabilities of Mesoblast have increased by 11.73% increased compared to the previous year.

What are the consequences of high debt for investors of Mesoblast?

High liabilities can pose a risk for investors of Mesoblast, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Mesoblast?

Low liabilities mean that Mesoblast has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Mesoblast affect the company?

An increase in liabilities of Mesoblast can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Mesoblast affect the company?

A decrease in the liabilities of Mesoblast can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Mesoblast?

Some factors that can influence the liabilities of Mesoblast include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Mesoblast so important for investors?

The liabilities of Mesoblast are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Mesoblast take to modify the liabilities?

To change its liabilities, Mesoblast can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Mesoblast pay?

Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.

What is the dividend yield of Mesoblast?

The current dividend yield of Mesoblast is .

When does Mesoblast pay dividends?

Mesoblast pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mesoblast?

Mesoblast paid dividends every year for the past 0 years.

What is the dividend of Mesoblast?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mesoblast located?

Mesoblast is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mesoblast from 10/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2025.

When did Mesoblast pay the last dividend?

The last dividend was paid out on 10/4/2025.

What was the dividend of Mesoblast in the year 2024?

In the year 2024, Mesoblast distributed 0 USD as dividends.

In which currency does Mesoblast pay out the dividend?

The dividends of Mesoblast are distributed in USD.